ArticlePLoS neglected tropical diseases2013
Secondary bacterial infections of buruli ulcer lesions before and after chemotherapy with streptomycin and rifampicin.
Article in PLoS neglected tropical diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Antimicrobial resistance in Africa: a systematic review.BMC infectious diseases · 2017Pooled it
- The combination of amoxicillin-clavulanic acid and ketoconazole in the treatment of Madurella mycetomatis eumycetoma and Staphylococcus aureus co-infection.PLoS neglected tropical diseases · 2014Trial
- Characterization of secondary bacterial infections in Buruli ulcer disease in Ghana: a focus on antimicrobial resistant Staphylococcus aureus.BMC infectious diseases · 2026Article
- Buruli ulcer.Nature reviews. Disease primers · 2025Review
- Antimicrobial resistant bacteria isolated from Buruli ulcer lesions in Ghana.PLoS neglected tropical diseases · 2025Article
- Improved protocols for isolation of Mycobacterium ulcerans from clinical samples.BMC microbiology · 2025Article
- Computational and GC-MS screening of bioactive compounds from Thymus Vulgaris targeting mycolactone protein associated with Buruli ulcer.Scientific reports · 2025Article
- Toward Understanding the Mechanism of Client-Selective Small Molecule Inhibitors of the Sec61 Translocon.Journal of molecular recognition : JMR · 2025Review
- Volatile organic compound detection of Buruli ulcer disease: Headspace analysis of Mycobacterium ulcerans and used gauzes of Buruli-compatible ulcers.PLoS neglected tropical diseases · 2024Article
- Bacterial diversity in Buruli ulcer lesions in Ghana.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- Stigma experiences, effects and coping among individuals affected by Buruli ulcer and yaws in Ghana.PLoS neglected tropical diseases · 2024Article
- Clinical and microbiological predictors of healing in Buruli ulcer disease.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- Mycobacterium ulcerans-Bordetella trematum chronic tropical cutaneous ulcer: A four-case series, Côte d'Ivoire.PLoS neglected tropical diseases · 2023Article
- Research article network analysis of polymicrobial chronic wound infections in Masanga, Sierra Leone.BMC infectious diseases · 2023Article
- Gold Panning-Related Chronic Cutaneous Ulcers in Guinea, West Africa.The American journal of tropical medicine and hygiene · 2023Article
- Efficacy of an Acid-Oxidizing Solution against Mycobacterium ulcerans.Antimicrobial agents and chemotherapy · 2022Article
- Pathogenicity and virulence ofVirulence · 2021Review
- Chronic wounds in Sierra Leone: Searching for Buruli ulcer, a NTD caused by Mycobacterium ulcerans, at Masanga Hospital.PLoS neglected tropical diseases · 2021Article
- Responses to chemical cross-talk between the Mycobacterium ulcerans toxin, mycolactone, and Staphylococcus aureus.Scientific reports · 2021Article
- Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions.BMC microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Buruli ulcer (BU), caused by Mycobacterium ulcerans is a chronic necrotizing skin disease. It usually starts with a subcutaneous nodule or plaque containing large clusters of extracellular acid-fast bacilli. Surrounding tissue is destroyed by the cytotoxic macrolide toxin mycolactone produced by microcolonies of M. ulcerans. Skin covering the destroyed subcutaneous fat and soft tissue may eventually break down leading to the formation of large ulcers that progress, if untreated, over months and years. Here we have analyzed the bacterial flora of BU lesions of three different groups of patients before, during and after daily treatment with streptomycin and rifampicin for eight weeks (SR8) and determined drug resistance of the bacteria isolated from the lesions. Before SR8 treatment, more than 60% of the examined BU lesions were infected with other bacteria, with Staphylococcus aureus and Pseudomonas aeruginosa being the most prominent ones. During treatment, 65% of all lesions were still infected, mainly with P. aeruginosa. After completion of SR8 treatment, still more than 75% of lesions clinically suspected to be infected were microbiologically confirmed as infected, mainly with P. aeruginosa or Proteus miriabilis. Drug susceptibility tests revealed especially for S. aureus a high frequency of resistance to the first line drugs used in Ghana. Our results show that secondary infection of BU lesions is common. This could lead to delayed healing and should therefore be further investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.